Clinical trial
Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP
NCT00374998 · European Vaccine Initiative, Other · Completed
Key facts
| NCT number | NCT00374998 |
|---|---|
| Title | Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP |
| Official title | A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule |
| Lead sponsor | European Vaccine Initiative, Other |
| Collaborators | University of Oxford Wellcome Trust |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria, Falciparum |
| Intervention type | Biological |
| Interventions | FP9-PP (FP9 polyprotein), MVA-PP (Modified Virus Ankara polyprotein) |
| Enrollment | 35 |
| Start date | Apr 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Sep 12, 2006 |
| Last update posted | Mar 1, 2007 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: